Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at Wedbush issued their Q2 2017 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued on Wednesday. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.80) per share for the quarter. Wedbush has a “Outperform” rating and a $26.00 price target on the stock. Wedbush also issued estimates for Corvus Pharmaceuticals’ Q3 2017 earnings at ($0.85) EPS, Q4 2017 earnings at ($0.62) EPS, FY2017 earnings at ($3.06) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.89) EPS, Q3 2018 earnings at ($1.01) EPS, Q4 2018 earnings at ($0.85) EPS, FY2018 earnings at ($3.51) EPS, FY2019 earnings at ($3.49) EPS, FY2020 earnings at ($3.39) EPS and FY2021 earnings at ($3.08) EPS.

Several other equities analysts have also recently weighed in on CRVS. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Monday, July 17th. Credit Suisse Group dropped their price objective on Corvus Pharmaceuticals from $26.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, July 4th. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Corvus Pharmaceuticals in a report on Tuesday, July 4th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $20.50.

ILLEGAL ACTIVITY NOTICE: “Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.’s Q2 2017 Earnings (NASDAQ:CRVS)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/07/research-analysts-set-expectations-for-corvus-pharmaceuticals-inc-s-q2-2017-earnings-nasdaqcrvs.html.

Shares of Corvus Pharmaceuticals (CRVS) opened at 12.26 on Monday. The stock’s 50 day moving average price is $11.94 and its 200 day moving average price is $12.94. The company’s market cap is $256.65 million. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.03.

In other Corvus Pharmaceuticals news, insider Richard A. Md Miller purchased 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 13th. The shares were bought at an average price of $9.88 per share, for a total transaction of $247,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Holdings A/S Novo purchased 20,000 shares of the firm’s stock in a transaction dated Friday, June 23rd. The stock was acquired at an average price of $10.95 per share, for a total transaction of $219,000.00. Following the purchase, the insider now owns 3,244,046 shares in the company, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.

Several institutional investors have recently modified their holdings of CRVS. Russell Investments Group Ltd. acquired a new position in shares of Corvus Pharmaceuticals during the fourth quarter valued at about $402,000. Essex Investment Management Co. LLC raised its position in shares of Corvus Pharmaceuticals by 46.7% in the first quarter. Essex Investment Management Co. LLC now owns 31,225 shares of the company’s stock valued at $649,000 after buying an additional 9,933 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Corvus Pharmaceuticals during the first quarter valued at about $331,000. TD Asset Management Inc. raised its position in shares of Corvus Pharmaceuticals by 8.1% in the first quarter. TD Asset Management Inc. now owns 24,049 shares of the company’s stock valued at $499,000 after buying an additional 1,805 shares during the last quarter. Finally, TFS Capital LLC acquired a new position in shares of Corvus Pharmaceuticals during the first quarter valued at about $356,000. Institutional investors own 82.87% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.